Fig. 2From: Linagliptin and cardiovascular outcomes in type 2 diabetes after acute coronary syndrome or acute ischemic strokeEvent-free survival curves in each study group for a primary composite outcome, b cardiovascular death, c non-fatal myocardial infarction, d non-fatal ischemic stroke. Primary composite outcome included cardiovascular death, non-fatal myocardial infarction and non-fatal ischemic stroke. No significant differences in the primary composite outcome were observed between these two study groups after a 15-month follow-upBack to article page